西妥昔单抗联合FOLFOX方案治疗结直肠癌的临床效果  

Clinical efficacy of cetuximab combined FOLFOX chemotherapy treatment on colon and colorectal cancer

作　　者：李丽萍[1] 刘劲松[1] 

机构地区：[1]湖北省仙桃市第一人民医院肿瘤科,433000

出　　处：《中国综合临床》2014年第2期190-192,共3页Clinical Medicine of China

摘　　要：目的 观察西妥昔单抗联合FOLFOX方案治疗结、直肠癌的临床效果.方法 2009年3月至2012年3月我院收治结、直肠癌患者40例,应用数字表随机分为观察组与对照组,每组20例.对照组患者给予奥沙利铂＋亚叶酸钙＋5氟尿嘧啶进行治疗;观察组患者在对照组的基础上加用西妥昔单抗,首次剂量400 mg/m2,每周1次,第2周以后为250 mg/m2,每周1次,共6周.对两组患者的临床效果、毒副反应以及1年生存率进行比较.结果 治疗6周后,观察组完全缓解1例,部分缓解11例,疾病稳定5例,进展3例,总有效率为60％ （12/20）,临床受益率为85％ （17/20）;对照组部分缓解6例,疾病稳定7例,进展7例,总有效率为30％ （6/20）,临床受益率为65％ （13/20）.观察组的总有效率和临床受益率均显著优于对照组（x2值分别为18.18、10.67,P均＜0.05）.观察组的皮疹发生率为55％.（11/20）,显著高于对照组的15％（3/20）,差异有统计学意义（x2 =35.16,P ＜0.05）;观察组患者的半年生存率和1年生存率分别为75％ （15/20）和45％ （9/20）,显著高于对照组[50％（10/20）和25％（5/20）],差异有统计学意义（x2值分别为13.33、8.79,P均＜0.05）.结论 西妥昔单抗联合FOLFOX化疗方案治疗晚期结直肠癌疗效显著,毒副反应小,值得推广应用.Objective To explore the clinical efficacy of cetuximab combined FOLFOX chemotherapy on colon and colorectal cancer.Methods Forty patients with colon and colorectal cancer were randomly divided into observation group and control group,and 20 cases for each group.Patients in control group were treated with oxaliplatin ＋ leucovorin ＋ 5-fluorouracil,and in the observation group were given cetuximab （the first does was 400 mg/m2 at the first week,then the second week and follow weeks was 250 mg/m2 1 time/week for 6 week） plus the treatment as control group.The clinical efficacy,adverse effect and 1-year survival in the two groups were recorded.Results The total effective rate and clinical benefit rate in observation group were 60％ （12/20）and 85％ （17/20） respectively,which significantly higher than the control group （30％ （6/20） and 65 ％ （13/ 20）,x2 =18.18,10.67,P ＜ 0.05）.Skin rash rate in observation group was 55％ （11/20）,which was significantly higher than that of control group （15％ （3/20）,x2 =35.16,P ＜0.05）.Half-year survival rate and 1-year survival rate of patients in observation group were 75％ （15/20） and 45％ （9/20） respectively,significantly higher than the control group （50％ （10/20） and 25％ （5/20）,x2 =13.33,8.791,P ＜ 0.05）~ Conclusion Treatment scheme of Cetuximab combined FOLFOX chemotherapy is proved to be an effect of treating advanced colon and colorectal and be with the low adverse effect.

关 键 词：西妥昔单抗 结直肠癌 FOLFOX方案 

分 类 号：R735.3[医药卫生—肿瘤]